Tech Company Financing Transactions
MabVax Therapeutics Funding Round
MabVax Therapeutics closed a $8 million Series A financing round on 3/21/2008. Investors included GBP Capital.
Transaction Overview
Company Name
Announced On
3/21/2008
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
GBP Capital (Douglas Lind)
Proceeds Purpose
The company will use the proceeds to continue development on its cancer-fighting technologies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11535 Sorrento Valley Rd. 400
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
MabVax Therapeutics, Inc. is a San Diego, California based immunotherapeutics discovery and development company focused on developing and commercializing novel vaccines and human antibodies for the treatment of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Hansen
Chief Financial Officer
Gregory Hanson
Chief Scientific Officer
Philip Livingston
Vice President
Wolfgang Scholz
VP - Bus. Development
Paul Resnick
VP - R & D
Paul Maffuid
Browse more venture capital transactions:
Prev: 3/21/2008: NanoInk venture capital transaction
Next: 3/24/2008: Moxie venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs